EXACT Sciences Corporation Stock News

Exact Sciences' (EXAS) Laboratory and OncoExtra test gets selected by the NCI for ComboMATCH trials.

The Nasdaq has taken a rather large hit in recent weeks, sinking about 7.5% between July 18 and Aug 17. Two of the main reasons for the decline are worries about U.S. inflation and the Chinese econom

Growing revenue, an improving bottom line, and exciting opportunities paint a bright future for Exact Sciences. Novo Nordisk is virtually unmatched in the diabetes drug market, with more potential med

Exact Sciences has the potential to be a big name in cancer testing and screening in the future. It already has multiple tests, and is working on one that can screen for multiple cancers.

Growth stocks have stormed back to life in recent weeks. Exact Sciences and Vertex Pharmaceuticals should benefit from this shift in sentiment, thanks to their strong innovation, rising sales, and ste

Exact Sciences improved revenue and trimmed its losses, compared to the same period last year. The company also upgraded guidance for yearly revenue.

Exact Sciences posted consensus-topping financials yesterday. Even so, the biotech's shares are in the red by double digits today.

Strength in Screening revenues and Precision Oncology drive Exact Sciences (EXAS) Q2 performance.

Exact Sciences Corporation (NASDAQ:EXAS ) Q2 2023 Earnings Call Transcript August 1, 2023 5:00 PM ET Company Participants Megan Jones - Vice President of Investor Relations Kevin Conroy - Chairman and

Exact Sciences (EXAS) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.50. This compares to loss of $0.94 per share a year ago.

Exact Sciences (EXAS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

With technology advancing at a breakneck speed, investors – having taken care of their core portfolio needs – should consider must-know growth stocks with their discretionary funds. Unlike blue-ch

Exact Sciences develops innovative diagnostics tests that help intercept cancer early. Intuitive Surgical's famous robotic surgical system has important benefits for patients.

Cathie Wood's Ark Innovation ETF has been blazing the comeback trail in 2023. Among the fund's various holdings, Twist Biosciences and Exact Sciences stand out as top growth plays right now.

We have narrowed our search to five Nasdaq Composite listed non-technology stocks. These are: CELH, DKNG, CPRT, EXAS, MAR.